130 related articles for article (PubMed ID: 26645151)
21. [Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy].
Alves F; Hiddemann W
Internist (Berl); 1997 Nov; 38(11):1074-82. PubMed ID: 9453957
[No Abstract] [Full Text] [Related]
22. Tyrosine kinase inhibitor special issue.
Thamm DH
Vet Comp Oncol; 2012 Sep; 10(3):161-2. PubMed ID: 22882484
[No Abstract] [Full Text] [Related]
23. Protein tyrosine phosphatases as novel targets in breast cancer therapy.
Nunes-Xavier CE; Martín-Pérez J; Elson A; Pulido R
Biochim Biophys Acta; 2013 Dec; 1836(2):211-26. PubMed ID: 23756181
[TBL] [Abstract][Full Text] [Related]
24. The era of targeted therapies: increasing role for novel oncologic drugs in dermatology.
Montella L; Palmieri G; Lacouture M
Arch Dermatol; 2007 Jun; 143(6):788-9. PubMed ID: 17576948
[No Abstract] [Full Text] [Related]
25. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
26. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Magné N; Chargari C; Castadot P; Ghalibafian M; Soria JC; Haie-Meder C; Bourhis J; Deutsch E
Eur J Cancer; 2008 Oct; 44(15):2133-43. PubMed ID: 18692389
[TBL] [Abstract][Full Text] [Related]
28. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
29. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Neill MG; Wei AC; Jewett MA
Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
[TBL] [Abstract][Full Text] [Related]
30. Synergistic approach to cancer therapy: exploiting interactions between anti-estrogens, retinoids, monoterpenes and tyrosine kinase inhibitors.
Lackey BR; Gray SL; Henricks DM
Med Hypotheses; 2000 May; 54(5):832-6. PubMed ID: 10859696
[TBL] [Abstract][Full Text] [Related]
31. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
32. Targeted anti-cancer therapy in the elderly.
Gonsalves W; Ganti AK
Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391
[TBL] [Abstract][Full Text] [Related]
33. Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well.
Sobrero A; Andretta V
Onkologie; 2008 May; 31(5):224-5. PubMed ID: 18497509
[No Abstract] [Full Text] [Related]
34. Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Santarpia M; Gil N; Rosell R
Expert Rev Clin Pharmacol; 2015; 8(4):461-77. PubMed ID: 26068305
[TBL] [Abstract][Full Text] [Related]
35. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Ocaña A; Amir E
Cancer Treat Rev; 2009 Dec; 35(8):685-91. PubMed ID: 19733440
[TBL] [Abstract][Full Text] [Related]
36. The advent of targeted therapeutics and implications for pathologists.
Hess JL
Am J Clin Pathol; 2002 Mar; 117(3):355-7. PubMed ID: 11888074
[No Abstract] [Full Text] [Related]
37. Tyrosine kinase inhibitors in pediatric malignancies.
Skolnik JM; Adamson PC
Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
[TBL] [Abstract][Full Text] [Related]
38. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition.
Caffa I; D'Agostino V; Damonte P; Soncini D; Cea M; Monacelli F; Odetti P; Ballestrero A; Provenzani A; Longo VD; Nencioni A
Oncotarget; 2015 May; 6(14):11820-32. PubMed ID: 25909220
[TBL] [Abstract][Full Text] [Related]
39. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
40. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
Joensuu H
Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
